New methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
List view / Grid view
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
In this article, Janssen Pharmaceuticals’ Global Head of Discovery Neuroscience discusses the findings of their recent study which highlighted new roles for two gene products involved in human deafness which could enable drug discovery for some prevalent auditory disorders.
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BenevolentAI, a British artificial intelligence company has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen...
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
16 March 2016 | By Victoria White
JLINX is designed to catalyse scientific innovations by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem...
21 December 2015 | By Victoria White
Their goal is to develop a therapeutic vaccine which aims to intercept HPV infection-related disease, particularly in those who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer...
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
28 September 2015 | By Victoria White
The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research with a drug candidate in a proof-of-concept disease model of allergic asthma...
25 August 2015 | By Victoria White
Scientists from The Scripps Research Institute (TSRI) and Janssen have found a way to induce antibodies to fight a wide range of influenza subtypes...
22 May 2015 | By Victoria White
Achillion and Janssen have entered into a worldwide license and collaboration arrangement to develop and commercialise one or more of Achillion's HCV assets...
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787...
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...